

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### Tixagevimab–cilgavimab for preventing COVID-19 [ID6136]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The following points were raised during the consultation:

- Those eligible for prophylaxis of COVID-19 with tixagevimab-cilgavimab are more likely to be those covered under the protected characteristics in the equality act due to long-term health problems and disabilities.
- It is more likely that those with long-term health problems and/or multiple morbidities will also be more likely to be experiencing socioeconomic deprivation. Travel to treatment centres or hospitals may present additional cost barriers to treatment.
- Those eligible are also more likely to experience mobility difficulties or be homed in health and social care settings (learning disability, older people, mental health).

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will consider carefully if its recommendations make access to tixagevimab-cilgavimab more difficult for certain groups.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No additional stakeholders related to potential equality issues were identified during the scoping process.

**Approved by Associate Director (name):** Ross Dent  
**Date:** 19/08/2022